EKSO Ekso Bionics Holdings Inc

Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024

Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024

SAN RAFAEL, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2024 after the close of trading on Monday, April 29, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

A live webcast of the event will be available in the “Investors” section of the Company’s website at , or by . Investors interested in listening to the conference call may do so by dialing 877-407-3036 for domestic callers or 201-378-4919 for international callers.

A webcast replay will also be available on the Company’s website for one month following the completion of the call.

About Ekso Bionics® 

Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: or follow @EksoBionics on X.

Contact:

David Carey

212-867-1768



EN
22/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ekso Bionics Holdings Inc

 PRESS RELEASE

Ekso Bionics Announces First Quarter 2024 Financial Results

Ekso Bionics Announces First Quarter 2024 Financial Results SAN RAFAEL, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2024. Recent Highlights and Accomplishments Received final payment determination for Medicare reimbursement from the Centers for Medicare & Medicaid Services (“CMS”) for Ekso Indego PersonalReported revenues of $3.8 million for the first quarter of 2024...

 PRESS RELEASE

Ekso Bionics to Report First Quarter 2024 Financial Results on April 2...

Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024 SAN RAFAEL, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2024 after the close of trading on Monday, April 29, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. A live webcast of the even...

 PRESS RELEASE

Ekso Bionics Receives Final Payment Determination for Medicare Reimbur...

Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal SAN RAFAEL, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Pricing, Data Analysis, and Coding (“PDAC”) contractor for the Centers for Medicare & Medicaid Services (“CMS”) has determined a final payment level of $91,031.93 for Medicare reimbursement of the Ekso ...

 PRESS RELEASE

Ekso Bionics Reports Record Annual Revenue of $18.3 Million

Ekso Bionics Reports Record Annual Revenue of $18.3 Million Sold Record Number of Annual EksoHealth Units in 2023 SAN RAFAEL, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2023. Recent Highlights and Accomplishments Achieved record revenue of $18.3 million for the 2023 full year, an increase of 42% year-over-yearSold a total of 151 EksoHealth units for the 2023 full...

 PRESS RELEASE

Ekso Bionics to Report Fourth Quarter and Full Year 2023 Financial Res...

Ekso Bionics to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024 SAN RAFAEL, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2023 after the close of trading on Monday, March 4, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch